NOVAVAX INC Insider Trading for March 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NOVAVAX INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NOVAVAX INC for March 2021.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 5.95 | 2,062 | 12,269 | 61,876 | |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 46.00 | 416 | 19,136 | 8,759 | |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 27.60 | 416 | 11,482 | 3,760 | |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 196.12 | 47 | 9,218 | 275 | 322 to 275 (-14.60 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 194.74 | 56 | 10,905 | 322 | 378 to 322 (-14.81 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 192.82 | 151 | 29,116 | 378 | 529 to 378 (-28.54 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 191.38 | 245 | 46,888 | 529 | 774 to 529 (-31.65 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 190.10 | 252 | 47,905 | 774 | 1 K to 774 (-24.56 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 189.07 | 164 | 31,007 | 1,026 | 1.2 K to 1 K (-13.78 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 187.08 | 164 | 30,681 | 1,190 | 1.4 K to 1.2 K (-12.11 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 185.74 | 1,075 | 199,665 | 1,354 | 2.4 K to 1.4 K (-44.26 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 184.59 | 145 | 26,766 | 2,429 | 2.6 K to 2.4 K (-5.63 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 183.35 | 256 | 46,937 | 2,574 | 2.8 K to 2.6 K (-9.05 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 181.86 | 171 | 31,099 | 2,830 | 3 K to 2.8 K (-5.70 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 181.09 | 168 | 30,423 | 3,001 | 3.2 K to 3 K (-5.30 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 5.95 | 2,062 | 12,269 | 3,169 | 1.1 K to 3.2 K (+186.27 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 46.00 | 416 | 19,136 | 1,107 | 691 to 1.1 K (+60.20 %) |
Mar 30 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 27.60 | 416 | 11,482 | 691 | 275 to 691 (+151.27 %) |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Option Exercise | M | 3.99 | 37,500 | 149,438 | 0 | |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Option Exercise | M | 27.60 | 10,000 | 276,000 | 0 | |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Option Exercise | M | 46.00 | 10,000 | 460,000 | 0 | |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Buy | M | 3.99 | 37,500 | 149,438 | 57,500 | 20 K to 57.5 K (+187.50 %) |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Buy | M | 27.60 | 10,000 | 276,000 | 20,000 | 10 K to 20 K (+100.00 %) |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Sell | S | 229.41 | 2,446 | 561,134 | 10,000 | 12.4 K to 10 K (-19.65 %) |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Sell | S | 228.42 | 3,120 | 712,661 | 12,446 | 15.6 K to 12.4 K (-20.04 %) |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Sell | S | 227.43 | 4,434 | 1,008,435 | 15,566 | 20 K to 15.6 K (-22.17 %) |
Mar 25 2021 | NVAX | NOVAVAX INC | YOUNG JAMES F | Director | Buy | M | 46.00 | 10,000 | 460,000 | 20,000 | 10 K to 20 K (+100.00 %) |
Mar 23 2021 | NVAX | NOVAVAX INC | MCMANUS MICHAEL A JR | Director | Sell | S | 220.57 | 3,000 | 661,710 | 5,951 | 9 K to 6 K (-33.52 %) |
Mar 23 2021 | NVAX | NOVAVAX INC | MCMANUS MICHAEL A JR | Director | Sell | S | 221.40 | 1,000 | 221,400 | 8,951 | 10 K to 9 K (-10.05 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Option Exercise | M | 3.99 | 18,000 | 71,730 | 0 | |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Option Exercise | M | 46.00 | 4,500 | 207,000 | 0 | |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Option Exercise | M | 99.80 | 2,000 | 199,600 | 0 | |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Sell | S | 212.00 | 14,768 | 3,130,816 | 16,099 | 30.9 K to 16.1 K (-47.84 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Sell | S | 210.00 | 9,732 | 2,043,720 | 30,867 | 40.6 K to 30.9 K (-23.97 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Buy | M | 3.99 | 18,000 | 71,730 | 40,599 | 22.6 K to 40.6 K (+79.65 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Buy | M | 46.00 | 4,500 | 207,000 | 22,599 | 18.1 K to 22.6 K (+24.86 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | EVANS GARY C | Director | Buy | M | 99.80 | 2,000 | 199,600 | 18,099 | 16.1 K to 18.1 K (+12.42 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 56,462 | |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 68,752 | |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 16,322 | |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 6,605 | |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 1,861 | |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 225.89 | 129 | 29,140 | 2,811 | 2.9 K to 2.8 K (-4.39 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 224.78 | 375 | 84,292 | 2,940 | 3.3 K to 2.9 K (-11.31 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 223.86 | 164 | 36,713 | 3,315 | 3.5 K to 3.3 K (-4.71 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 221.91 | 60 | 13,315 | 3,479 | 3.5 K to 3.5 K (-1.70 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 219.84 | 180 | 39,572 | 3,539 | 3.7 K to 3.5 K (-4.84 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 218.53 | 114 | 24,912 | 3,719 | 3.8 K to 3.7 K (-2.97 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 217.31 | 402 | 87,357 | 3,833 | 4.2 K to 3.8 K (-9.49 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 216.05 | 421 | 90,955 | 4,235 | 4.7 K to 4.2 K (-9.04 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 215.19 | 459 | 98,771 | 4,656 | 5.1 K to 4.7 K (-8.97 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 213.01 | 57 | 12,142 | 5,115 | 5.2 K to 5.1 K (-1.10 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 211.96 | 57 | 12,082 | 5,172 | 5.2 K to 5.2 K (-1.09 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 210.85 | 5 | 1,054 | 5,229 | 5.2 K to 5.2 K (-0.10 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 217.46 | 2,264 | 492,329 | 5,234 | 7.5 K to 5.2 K (-30.19 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 217.46 | 132 | 28,705 | 7,498 | 7.6 K to 7.5 K (-1.73 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 217.46 | 4,819 | 1,047,940 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 201.47 | 100 | 20,147 | 2,811 | 2.9 K to 2.8 K (-3.44 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 200.15 | 1,282 | 256,586 | 2,911 | 4.2 K to 2.9 K (-30.57 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 199.07 | 1,490 | 296,616 | 4,193 | 5.7 K to 4.2 K (-26.22 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 197.87 | 1,939 | 383,662 | 5,683 | 7.6 K to 5.7 K (-25.44 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 196.88 | 901 | 177,389 | 7,622 | 8.5 K to 7.6 K (-10.57 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 5.95 | 383 | 2,279 | 11,884 | |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 5.95 | 2,083 | 12,394 | 64,584 | |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 46.00 | 521 | 23,966 | 11,465 | |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 27.60 | 417 | 11,509 | 4,175 | |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 168.09 | 190 | 31,937 | 287 | 477 to 287 (-39.83 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Payment of Exercise | F | 174.84 | 179 | 31,296 | 477 | 656 to 477 (-27.29 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | D | 174.84 | 14 | 2,448 | 656 | 670 to 656 (-2.09 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 5.95 | 383 | 2,279 | 670 | 287 to 670 (+133.45 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 175.16 | 12 | 2,102 | 287 | 299 to 287 (-4.01 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 173.54 | 186 | 32,278 | 299 | 485 to 299 (-38.35 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 172.24 | 203 | 34,964 | 485 | 688 to 485 (-29.51 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 171.23 | 314 | 53,767 | 688 | 1 K to 688 (-31.34 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 170.26 | 336 | 57,206 | 1,002 | 1.3 K to 1 K (-25.11 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 168.89 | 91 | 15,369 | 1,338 | 1.4 K to 1.3 K (-6.37 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 167.73 | 167 | 28,011 | 1,429 | 1.6 K to 1.4 K (-10.46 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 166.48 | 263 | 43,784 | 1,596 | 1.9 K to 1.6 K (-14.15 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 163.53 | 162 | 26,492 | 1,859 | 2 K to 1.9 K (-8.02 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 160.82 | 172 | 27,661 | 2,021 | 2.2 K to 2 K (-7.84 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 159.02 | 101 | 16,061 | 2,193 | 2.3 K to 2.2 K (-4.40 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 157.08 | 160 | 25,133 | 2,294 | 2.5 K to 2.3 K (-6.52 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 155.64 | 135 | 21,011 | 2,454 | 2.6 K to 2.5 K (-5.21 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 154.00 | 185 | 28,490 | 2,589 | 2.8 K to 2.6 K (-6.67 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 153.25 | 312 | 47,812 | 2,774 | 3.1 K to 2.8 K (-10.11 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 152.40 | 150 | 22,859 | 3,086 | 3.2 K to 3.1 K (-4.64 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 150.31 | 72 | 10,822 | 3,236 | 3.3 K to 3.2 K (-2.18 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 5.95 | 2,083 | 12,394 | 3,308 | 1.2 K to 3.3 K (+170.04 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 46.00 | 521 | 23,966 | 1,225 | 704 to 1.2 K (+74.01 %) |
Mar 09 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 27.60 | 417 | 11,509 | 704 | 287 to 704 (+145.30 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 5.95 | 2,063 | 12,275 | 63,938 | |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 46.00 | 416 | 19,136 | 9,175 | |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 27.60 | 416 | 11,482 | 4,176 | |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 232.35 | 12 | 2,788 | 275 | 287 to 275 (-4.18 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 231.41 | 59 | 13,653 | 287 | 346 to 287 (-17.05 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 230.04 | 38 | 8,742 | 346 | 384 to 346 (-9.90 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 228.64 | 369 | 84,368 | 384 | 753 to 384 (-49.00 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 227.82 | 569 | 129,628 | 753 | 1.3 K to 753 (-43.04 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 226.59 | 538 | 121,905 | 1,322 | 1.9 K to 1.3 K (-28.92 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 225.45 | 248 | 55,913 | 1,860 | 2.1 K to 1.9 K (-11.76 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 224.93 | 120 | 26,991 | 2,108 | 2.2 K to 2.1 K (-5.39 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 223.48 | 188 | 42,014 | 2,228 | 2.4 K to 2.2 K (-7.78 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 222.39 | 227 | 50,483 | 2,416 | 2.6 K to 2.4 K (-8.59 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 221.32 | 250 | 55,330 | 2,643 | 2.9 K to 2.6 K (-8.64 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 220.33 | 168 | 37,016 | 2,893 | 3.1 K to 2.9 K (-5.49 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 219.55 | 109 | 23,930 | 3,061 | 3.2 K to 3.1 K (-3.44 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 5.95 | 2,063 | 12,275 | 3,170 | 1.1 K to 3.2 K (+186.36 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 46.00 | 416 | 19,136 | 1,107 | 691 to 1.1 K (+60.20 %) |
Mar 02 2021 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 27.60 | 416 | 11,482 | 691 | 275 to 691 (+151.27 %) |